New drug treats overactive bladder without drying mouth

LoBuono, Charlotte
January 2005
Drug Topics;1/10/2005, Vol. 149 Issue 1, p18
Trade Publication
This article reports on the approval of solifenacin for the treatment of overactive bladder with symptoms of urgency, urinary frequency, and urge urinary incontinence by the U.S. Food and Drug Administration. According to physician Peter Sand, a professor of obstetrics and gynecology and director of urogynecology at Northwestern University Feinberg School of Medicine in Chicago, vesicare is an anticholinergic, antimuscarinic agent with some relative specificity for the M3 receptors in the bladder. Some head-to-head data versus tolterodine and the data in the labeling indicate that solifenacin has the lowest rate of dry mouth among oral anticholinergics. The recommended dose of solifenacin is 5 mg, taken once daily. If the 5-mg dose is well tolerated, the dose may be increased to 10 mg, taken once daily.


Related Articles

  • FDA Actions.  // Neurology Alert;Jan2009 Pharmacology Watch, p2 

    The article reports on the approval of fesoterodine fumarate for the treatment of overactive bladder by the U.S. Food and Drug Administration (FDA). Manufactured by SchwartzPharma, the drug relaxes smooth muscle of the bladder reducing urinary frequency, urge to urinate, and sudden urinary...

  • BOTOX for bladder control. LOTEMPIO, SUSAN M. // New Mobility;Oct2013, Vol. 24 Issue 241, p14 

    The article offers the author's insight on her experience of Botox injections to regain control of her bladder. She relates her experience of work-related stress due to urinary incontinence and its impact on the quality of her life and those who have the disorder. She discusses how the Botox...

  • Botox OK for incontinence. Gustafson, Mary // McKnight's Long-Term Care News;Oct2011, Vol. 32 Issue 10, p3 

    The article reports on the approval of Botox (botulinum toxin type A) by the U.S. Food and Drug Administration (FDA) for treating incontinence in patients with neurologic conditions including spinal cord injury and overactive bladder.

  • Incontinence patch goes over-the-counter.  // FDA Consumer;Jul/Aug98, Vol. 32 Issue 4, p5 

    Reports on the approval of the over-the-counter sale of `UroMed Patch' by the United States Food and Drug Administration. Use of this patch to help women reduce leakage from stress urinary incontinence; Amount of Americans affected by urinary incontinence; Information on the patch manufactured...

  • Calm Your Busy Bladder.  // Cleveland Clinic Men's Health Advisor;Sep2013, Vol. 15 Issue 9, p3 

    The article offers new treatments and lifestyle changes that can help one's overactive bladder (OAB) to relax. The causes and treatments of OAB, which is defined as the need to urinate eight or more times a day or twice or more at night, along with an inability to delay urination is mentioned....

  • OTC Oxytrol for Women now available in retail pharmacies. Sobieraj, Diana M. // Drug Topics;Jan2014, Vol. 158 Issue 1, p64 

    The article reports on the approval of an alteration in status for Oxytrol under the product name Oxytrol for Women by the Food and Drug Administration (FDA) in the U.S. It mentions that the active ingredient in the patch of the drug is oxybutynin, delivered at 3.9 milligrams (mg) per day...

  • FDA Actions. Elliott, William T. // Clinical Cardiology Alert;Jan2009 Pharmacology, p2 

    The article reports on the approval by the U.S. Food and Drug Administration (FDA) in January 2009 of the drug fesoterodine fumarate. The drug is reportedly for the treatment of overactive bladder. The mechanism of action of the drug is described. Said drug is available in 4 milligrams (mg) and...

  • Toviaz approved to treat overactive bladders. Fernandez, Veronica // Drug Topics;3/1/2009, Vol. 153 Issue 3, pH12 

    The article discusses the approval of the Toviaz, an extended-release tablets for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency and frequency by the Food and Drug Administration in the U.S. It states that its approval was based on 12-week studies which...

  • New Products & Services.  // Urology Times;Jul2004, Vol. 32 Issue 10, p56 

    Presents products and services for urology. U.S. Food and Drug Administration's (FDA) approval of an oral drug for overactive bladder; Measurement of bladder fullness by a prosthetic management device; FDA's approval of systems for prolapse repair.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics